[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628663":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Texas at Austin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Enrolled Patients",null,"Adult patients (\\>18 years) who have seen a CommUnityCare provider in the previous 12 months at time of enrollment, who have a documented history of clinical ASCVD, and are not achieving LDL targets (either \\\u003C55 or \\\u003C70 mg\u002FdL based on risk factors)",[13],"Behavioral: Pharmacy Intern Counseling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BEHAVIORAL","Pharmacy Intern Counseling","The research intervention consists of outreach conducted by a Texas-licensed pharmacist intern under the supervision of CuC-employed pharmacists. Eligible patients will be contacted by a student pharmacist after the clinical pharmacists' appointment (described above in the standard of care) using CuC's RingCentral telehealth system. During this outreach, student pharmacists will review current lipid-lowering therapies, medication adherence, education about lipid-lowering therapies, and review of labs. Student pharmacists will not make independent prescribing or care decisions. All prescribing authority and therapeutic adjustments remain under the direction of CuC-employed pharmacists in accordance with the standard operating procedures. Patients will be informed about the research project during the outreach call or during a separate call dedicated to recruitment prior to the outreach call. Informed consent will be sent and obtained via either the EHR messaging system (MyChart) or text",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Morgan Stewart, PharmD","CONTACT","5129789096","morgan.stewart@austin.utexas.edu",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Kathryn Lin, PharmD","512-978-8593","kathryn.lin@austin.utexas.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CommUnityCare Health Centers","RECRUITING","Austin","Texas","78741","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-97.74306,30.26715,{"lat":43,"lon":42},[46,48,51,53],{"name":22,"role":23,"phone":47,"phoneExt":10,"email":25},"512-978-9096",{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},"Madison Tran","SUB_INVESTIGATOR",{"name":52,"role":50,"phone":10,"phoneExt":10,"email":10},"Khue (Chloe) Dao",{"name":27,"role":50,"phone":10,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Morgan Stewart","Clinical Associate Professor","100628663","optimizing-non-statin-agents-for-ascvd-100628663",false,"NCT07464574","Optimizing Non-statin Agents for ASCVD","Using Pharmacy Extenders to Optimize Non-statin Agents for Secondary ASCVD Prevention Outcomes in a Federally Qualified Health Center","Inclusion Criteria:\n\n* Adult patients (\\>18 years) who have seen a CommUnityCare provider in the previous 12 months at time of enrollment, who have a documented history of clinical ASCVD, and are not achieving LDL targets (either \\\u003C55 or \\\u003C70 mg\u002FdL based on risk factors)\n\nExclusion Criteria:\n\n* Patients will be excluded if they do not have a clearly documented history clinical ASCVD, are already achieving LDL targets (either \\\u003C55 or \\\u003C70 mg\u002FdL based on risk factors), having cholesterol managed by outside provider (e.g. outside cardiologist\u002Flipid specialist), current pregnancy, have not seen a CUC provider in the previous 12 months, or otherwise do not qualify for clinical pharmacy intervention","ALL","18 Years",{"count":68,"type":69},1000,"ESTIMATED","6 Months","OBSERVATIONAL","* The purpose of the study is to improve care for patients with high cholesterol.\n* If you choose to join the study, you will be asked to answer a phone call from study personnel. They will help you coordinate follow up appointments, review your medications and lab with you, and answer any questions you have about your medications. You will also continue to be seen by a clinical pharmacy team member. Your cholesterol medications may change to better lower your cholesterol. We will collect information about your visits, medicines, and cholesterol levels for 6 months.\n* If you choose not to participate, you will receive the same information and treatment at your next scheduled visit. You will receive the same care regardless of choosing to participate in the study.\n* Participation might involve a very low risk of some loss of privacy. There is low risk that someone outside the research study could see information about you.\n* A possible benefit is lower cholesterol.\n* Taking part in this research study is your choice. You do not have to participate, and you can stop at any time without any penalty.",[74],"ASCVD Management",[76],"non-statin","2026-03-05",{"date":79,"type":80},"2026-03-11","ACTUAL",{"date":82,"type":80},"2026-01-16",{"date":84,"type":69},"2027-05-01",{"name":5,"class":6},1]